Clinical trial register · United States · industry-sponsored

Clinical Trials in Alabama, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC

9144

Studies in scope

industry-sponsored, all four open statuses

4957

Recruiting now

open to new participants

2196

Lead sponsors

across recruiting studies

Top states

California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246

Trials with a site in Alabama

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Alabama, Florida, Pennsylvania

2026-12-16

Not yet open

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

NCT07850050Obesity

Boehringer Ingelheim

Phase 3

600

Alabama, California, Florida, Louisiana, Maryland, North Carolina, Utah

2026-10-31

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-10-26

Recruiting

Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure

NCT07775495Healthy Adult Participants

Ecotera Health LLC

Observational

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware

2026-10-21

Not yet open

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

NCT06458907Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure

P+F Products + Features USA Inc.

Not applicable

780

Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kansas

2026-10

Not yet open

Signatera Assessment in Early-Stage Endometrial Cancer

NCT07339384Endometrial Cancer

Natera, Inc.

Not applicable

1,010

Alabama, California, Florida, Illinois, Minnesota, New York, North Carolina, Ohio

2026-10

Not yet open

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

NCT07814417Colorectal Neoplasms

DrugsLeucovorin/levofolinate calcium·Olomorasib·Cetuximab·Adrucil

Eli Lilly and Company

Phase 2

Alabama, California, Florida, Massachusetts, New Jersey, Texas, Virginia, Wisconsin

2026-10

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

NCT07843472Obesity or Overweight, Cardiovascular Disease

Hoffmann-La Roche

Phase 3

2,500

Alabama, California, Florida

2026-09-30

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

NCT07843498Obesity or Overweight

Hoffmann-La Roche

Phase 3

3,900

Alabama, Florida, Tennessee

2026-09-30

Recruiting

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

NCT07845500Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity

DrugsBerobenatide·Tirzepatide·Semaglutide

Pfizer

Phase 3

660

Alabama, California, Florida, Kentucky, Michigan, Mississippi, Missouri, Montana

2026-09-30

Recruiting

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

NCT07775924Cutaneous Lichen Planus

DrugGIA632

Novartis Pharmaceuticals

Phase 2

259

Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan

2026-09-29

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois

2026-09-29

Recruiting

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury

NCT07799532Chronic Spinal Cord Injury

NervGen Pharma

Phase 3

150

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2026-09-28

Recruiting

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

NCT07819435Androgenetic Alopecia

Pelage Pharmaceuticals, Inc.

Phase 2/3

600

Alabama, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Minnesota

2026-09-21

Recruiting

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

NCT07830719Coronary Artery Disease

Novartis Pharmaceuticals

Phase 2

180

Alabama, California, Florida, Kansas, Maryland, Texas, Virginia

2026-09-18

Recruiting

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

NCT07823608Apnea, Sleep Disorders, Overweight and/or Obesity

DrugBerobenatide

Pfizer

Phase 3

258

Alabama, California, Florida, Minnesota, Texas

2026-09-17

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota

2026-09-17

Recruiting

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

NCT07587021Primary Hyperoxaluria Type 1, PH1

YolTech Therapeutics Co., Ltd

Phase 2

Alabama, Colorado, Missouri, Pennsylvania

2026-09-16

Not yet open

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

NCT07284745Irritability Associated With Autism Spectrum Disorder

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

176

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky

2026-09-11

Recruiting

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

NCT07321899Severe Tricuspid Regurgitation

Medtronic Cardiovascular

Not applicable

1,186

Alabama, Arizona, California, Connecticut, Georgia, Illinois, Minnesota, New York

2026-09-11

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas

2026-09-08

Recruiting

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

NCT07794748Pneumococcal Disease

DrugPrevnar 20

Pfizer

Phase 3

4,670

Alabama, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa

2026-09-08

Recruiting

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

NCT07805707Influenza, Human

GlaxoSmithKline

Phase 3

54,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2026-09-02

Recruiting

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305Renal Insufficiency, Chronic

DrugsBalcinrenone/dapagliflozin·Dapagliflozin

AstraZeneca

Phase 3

2,800

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois

2026-09-01

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

NCT07594119Focal Seizure, Epilepsy, Focal Epilepsy

DrugRAP-219

Rapport Therapeutics Inc.

Phase 3

312

Alabama, Arkansas, Colorado, Florida, Hawaii, Illinois, Nebraska, New York

2026-09

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463Obesity, Overweight, Chronic Weight Management

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

3,003

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho

2026-08-31

Recruiting

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

NCT07720271Overweight, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

950

Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana

2026-08-31

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

1,560

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho

2026-08-28

Recruiting

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

576

Alabama, Arizona, Arkansas, California, Colorado, Georgia, Illinois, Maryland

2026-08-27

Recruiting

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension

DrugClazakizumab

Eli Lilly and Company

Phase 2

120

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts

2026-08-27

Recruiting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal

DrugOrforglipron

Eli Lilly and Company

Phase 3

2,001

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-08-26

Recruiting

A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation

NCT07527299Atrial Fibrillation

Biosense Webster, Inc.

Not applicable

1,070

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Kentucky, New York

2026-08-26

Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)

DrugDanicamtiv

Kardigan, Inc.

Phase 3

332

Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts

2026-08-26

Recruiting

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

NCT07795814Heart Failure With Preserved Ejection Fraction

Edgewise Therapeutics, Inc.

Phase 2

Alabama, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland

2026-08-25

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia

2026-08-24

Recruiting

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335Type 2 Diabetes, Cardiovascular Risk

DrugZenagamtide

Novo Nordisk A/S

Phase 3

1,778

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana

2026-08-24

Recruiting

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

NCT07754461Type 2 Diabetes

DrugSurvodutide

Boehringer Ingelheim

Phase 3

600

Alabama, Arizona, Arkansas, California, Florida, Georgia, Hawaii, Idaho

2026-08-24

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2026-08-21

Recruiting

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542Hidradenitis Suppurativa (HS)

DrugORKA-002

Oruka Therapeutics, Inc.

Phase 2

200

Alabama, California, Connecticut, Georgia, Illinois, Louisiana, Michigan, Minnesota

2026-08-21

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725Obesity or Overweight

DrugLenbelintide

AstraZeneca

Phase 3

2,500

Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Michigan

2026-08-19

Recruiting

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

NCT07723924Functional Constipation (FC)

Bausch Health Americas, Inc.

Phase 2

180

Alabama, Arkansas, California, Florida, Georgia, Kansas, Louisiana, Maryland

2026-08-18

Recruiting

A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)

NCT07595263Healthy

DrugMethadone

Merck Sharp & Dohme LLC

Phase 1

Alabama

2026-08-17

Recruiting

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

NCT07765888Atopic Dermatitis

DrugTilrekimig

Pfizer

Phase 3

375

Alabama, Arizona, California, Florida, Georgia, North Dakota, Texas

2026-08-17

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts

2026-08-14

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131Hypercholesterolaemia

DrugsRosuvastatin 1·Rosuvastatin 2

AstraZeneca

Phase 3

600

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2026-08-12

Recruiting

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841Overweight, Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

450

Alabama, California, Florida, Hawaii, Kentucky, Missouri, Nevada, Oregon

2026-08-12

Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain

NCT07641504Chronic Pain, Low Back Pain

DrugLY4065967

Eli Lilly and Company

Phase 2

150

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-08-12

Recruiting

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973Overweight , Obesity, Adults

DrugALV-100

Alveus Therapeutics, Inc.

Phase 2

220

Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan

2026-08-10

Recruiting

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

NCT07626411Atrial Fibrillation (AF)

DrugsCenvacibart·Apixaban

Regeneron Pharmaceuticals

Phase 3

15,364

Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana

2026-08-10

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07759245Pulmonary Disease, Chronic Obstructive

DrugBrenipatide

Eli Lilly and Company

Phase 2

606

Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan

2026-08-07

Recruiting

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07711418Moderate-to-Severe Atopic Dermatitis

DrugRezpegaldesleukin

Nektar Therapeutics

Phase 3

510

Alabama, California, Florida, Georgia, Louisiana, Missouri, Nevada, New Jersey

2026-08-07

By invitation

An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

NCT07773883ADHD

DrugSolriamfetol

Axsome Therapeutics, Inc.

Phase 3

300

Alabama, Arkansas, Florida, South Carolina, Tennessee

2026-08-06

Recruiting

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

NCT07752979Obesity, Overweight

DrugABBV-295

AbbVie

Phase 2

360

Alabama, Arizona, California, Florida, Idaho, Illinois, Kentucky, Mississippi

2026-08-04

Recruiting

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07674654Acute Migraine

DrugElismetrep

Kallyope Inc.

Phase 3

1,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois

2026-08-03

Recruiting

A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

NCT07727538Familial Chylomicronemia Syndrome

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

Alabama, California, Texas, Washington

2026-07-31

Recruiting

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

NCT07521007Atherosclerosis, Coronary Artery Disease

Beijing Inno Medicine Co., Ltd.

Phase 2

456

Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri

2026-07-31

Recruiting

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

NCT07697456Crohn's Disease, Ulcerative Colitis

DrugsABBV-701·Trosunilimab·Risankizumab

AbbVie

Phase 2

2,000

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-07-31

Recruiting

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640Steno-occlusive Disease

DrugsGadopiclenol·Gadoterate meglumine

Guerbet

Phase 3

315

Alabama, California, Colorado, Illinois, Minnesota, Washington

2026-07-28

Recruiting

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT07685808Overweight or Obesity

DrugOlatorepatide

Regeneron Pharmaceuticals

Phase 2

360

Alabama, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Nebraska

2026-07-28

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Louisiana

2026-07-27

Recruiting

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235Obesity, Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

3,200

Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois

2026-07-23

Recruiting

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

NCT07734649Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers

DrugHMPV vaccine

Sanofi

Phase 1/2

2,400

Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana

2026-07-22

Recruiting

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

NCT07654374Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus

DrugAleniglipron

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

1,100

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho

2026-07-17

Recruiting

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

NCT07654361Obesity, Overweight, Chronic Weight Management

DrugAleniglipron

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

3,600

Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois

2026-07-13

Recruiting

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610Peripheral Artery Disease (PAD)

DrugsAmrecibart·Cenvacibart·Rivaroxaban

Regeneron Pharmaceuticals

Phase 3

7,050

Alabama, Arizona, Arkansas, California, Florida, Indiana, Louisiana, North Carolina

2026-07-10

Recruiting

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

NCT07665437Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

710

Alabama, Arkansas, California, Florida, Illinois, Indiana, Nebraska, New York

2026-07-10

Recruiting

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

NCT07625280Narcolepsy, Idiopathic Hypersomnia

DrugXywav

Jazz Pharmaceuticals

Phase 3

120

Alabama, California, Colorado, Florida, Georgia, North Carolina, Ohio, Tennessee

2026-07-09

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

2,000

Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

800

Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky

2026-07-06

Recruiting

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

NCT07717879ADHD

DrugsSolriamfetol A·Solriamfetol B

Axsome Therapeutics, Inc.

Phase 3

468

Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi

2026-07-06

Recruiting

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213Type 2 Diabetes Mellitus

DrugsElecoglipron·Semaglutide

AstraZeneca

Phase 3

1,200

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-07-06

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07365241Small Cell Lung Cancer

DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan

AbbVie

Phase 3

531

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky

2026-07-02

Recruiting

Pridopidine Phase 3 Study in Huntington's Disease

NCT07609108Huntington Disease

DrugPridopidine

Prilenia

Phase 3

400

Alabama, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts

2026-07-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07645924Migraine

DrugElismetrep

Kallyope Inc.

Phase 3

1,800

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois

2026-07-01

Recruiting

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

NCT07614984Lipoprotein(a)

DrugsHRS-5346·Enlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 2

750

Alabama, California, Connecticut, Florida, Maryland, Michigan, Minnesota, Montana

2026-06-30

Recruiting

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

120

Alabama, California, Georgia, Illinois, Nebraska, New Mexico, Tennessee

2026-06-30

Active, closed

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

NCT07662122Obesity, Overweight

DrugBI 3034701

Boehringer Ingelheim

Phase 2

344

Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina

2026-06-30

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2026-06-29

Recruiting

Study of NTB-928 in R/R OC

NCT07690189Relapsed/Refractory Ovarian Carcinoma

TeneoSeven, Inc.

Phase 1

Alabama, Nebraska, New York, Texas

2026-06-29

Recruiting

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

NCT07717892ADHD

DrugsSolriamfetol A·Solriamfetol B

Axsome Therapeutics, Inc.

Phase 3

468

Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi

2026-06-25

Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

NCT07641517Osteoarthritis, Knee, Chronic Pain

DrugLY4065967

Eli Lilly and Company

Phase 2

150

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-06-25

Recruiting

A Study of Depemokimab in Participants of 6 to 11 Years of Age

NCT07671001Asthma

DrugDepemokimab

GlaxoSmithKline

Phase 3

Alabama, Colorado, South Dakota

2026-06-25

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388Diabetes Mellitus, Type 2

DrugsUBT251·Semaglutide

Novo Nordisk A/S

Phase 2

300

Alabama, California, Florida, Indiana, Kansas, Maryland, North Carolina, North Dakota

2026-06-22

Recruiting

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

NCT07505771Solid Malignancies

Immunome, Inc.

Phase 1

105

Alabama, California, Florida, Texas

2026-06-19

Active, closed

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT07477704Hypercholesterolemia

DrugsPraluent·Alirocumab

Regeneron Pharmaceuticals

Phase 2

438

Alabama, California, Florida, Georgia, Hawaii, Kentucky, Louisiana, Montana

2026-06-17

Recruiting

A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

NCT07606274LMNA-Related Dilated Cardiomyopathy

Nuevocor Pte. Ltd.

Phase 1/2

Alabama, California, Massachusetts, Michigan, Minnesota, Ohio, Texas

2026-06-16

Recruiting

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

NCT07660198Pneumococcal Disease

DrugsPG4·Prevnar 20

Pfizer

Phase 3

1,200

Alabama, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Massachusetts

2026-06-15

Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NCT07365319Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

DrugsEIK1001·Cisplatin/Carboplatin·Nab-paclitaxel·Pemetrexed

Eikon Therapeutics

Phase 2/3

750

Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee

2026-06-15

Recruiting

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

NCT07309445Non-Muscle Invasive Bladder Neoplasms

Janssen Research & Development, LLC

Observational

150

Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan

2026-06-12

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-06-11

Active, closed

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

NCT07639021Obesity

DrugsNNC0662-0419·Semaglutide

Novo Nordisk A/S

Phase 2

233

Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri

2026-06-09

Recruiting

An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

NCT07593391Phelan-McDermid Syndrome

DrugNNZ-2591

Neuren Pharmaceuticals Limited

Phase 3

180

Alabama, California, Maryland, Massachusetts, New York, Ohio, Texas

2026-06-08

Recruiting

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

DrugsArsenic Trioxide·ATRA

Quetzal Therapeutics

Phase 3

150

Alabama, California, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina

2026-06-08

Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Immuneering Corporation

Phase 3

510

Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois

2026-06-05

Recruiting

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

NCT07521137Candidiasis, Vulvovaginal

Sano Chemicals Inc

Phase 2

Alabama

2026-06-04

Recruiting

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

NCT07286331Neoplasms, Endometrial

DrugsMocertatug rezetecan·Doxorubicin·Paclitaxel

GlaxoSmithKline

Phase 3

600

Alabama, Nebraska

2026-06-04

Recruiting

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy

NCT07675135EDS, Cataplexy, Fatigue, Narcolepsy

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

258

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2026-06-04

Recruiting

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885Psoriasis

DrugD-2570

InventisBio Co., Ltd

Phase 2

Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky

2026-06-03

Recruiting

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

NCT07290140Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Airiver Medical, Inc.

Not applicable

300

Alabama, California, Colorado, Iowa, Kentucky, Pennsylvania, South Carolina, Texas

2026-06-01

Recruiting

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis

R1 Therapeutics

Phase 2

168

Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota

2026-06-01

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2026-05-31

Recruiting

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

NCT07629440Pneumococcal Disease

DrugsPG4·Prevnar 20

Pfizer

Phase 3

3,230

Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-05-29

Recruiting

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

NCT07610278Hypercholesterolaemia

DrugsQCZ484·Inclisiran

Novartis Pharmaceuticals

Phase 2

120

Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland

2026-05-29

Recruiting

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

NCT07598708Narcolepsy Type 1, Narcolepsy Type 2

Centessa Pharmaceuticals (UK) Limited

Phase 2/3

222

Alabama, Colorado, Florida, Georgia, Mississippi, North Carolina, Ohio, South Carolina

2026-05-29

Recruiting

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964Systemic Lupus Erythematosus, Rheumatoid Arthritis

AbbVie

Phase 1

Alabama, California, Florida, Illinois, Tennessee, Texas

2026-05-28

Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic

Apollo Therapeutics Ltd

Phase 2

280

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2026-05-28

Recruiting

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

NCT07527923Healthy Volunteer, Atopic Dermatitis

Regeneron Pharmaceuticals

Phase 1

144

Alabama, Arkansas, California, Florida, South Carolina, Texas

2026-05-22

Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT07492641HR+/HER2- Breast Cancer

DrugsBGB-43395·Abemaciclib·Ribociclib·Palbociclib

BeOne Medicines

Phase 3

1,056

Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Hawaii

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Alabama, Arizona, California, Connecticut, New Jersey, New York, Tennessee, Texas

2026-05-21

Recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414Obesity, Type 2 Diabetes

DrugsCagriSema·Semaglutide

Novo Nordisk A/S

Phase 3

2,500

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2026-05-21

Recruiting

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

NCT07428616Meningioma

DrugZanzalintinib

Exelixis

Phase 2

100

Alabama, Arizona, California, Florida, Illinois, Louisiana, Massachusetts, Missouri

2026-05-21

Recruiting

Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology

NCT07101809Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones

Calyxo, Inc.

Not applicable

150

Alabama, Florida, New York, Pennsylvania, Texas

2026-05-21

Recruiting

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

NCT06948214Growth Hormone Deficiency (GHD)

DrugLUM-201

Lumos Pharma

Phase 3

150

Alabama, California, Colorado, District of Columbia, Florida, Indiana, Iowa, Louisiana

2026-05-20

Recruiting

Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population

NCT07623902CRC Screening, Microbiome

Jubaan Ltd.

Not applicable

1,436

Alabama, California, Florida, Illinois, New York, Ohio, Virginia

2026-05-18

Recruiting

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098Breast Neoplasms

DrugsImlunestrant·Goserelin·Tamoxifen

Eli Lilly and Company

Phase 2

600

Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky

2026-05-13

Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001Obesity, Heart Failure

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

5,610

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2026-05-11

Recruiting

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

NCT07575399Obesity or Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

300

Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois

2026-05-11

Active, closed

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2026-05-11

Recruiting

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

218

Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri

2026-05-11

Recruiting

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

NCT07406360Measles, Measles-Mumps-Rubella+Chickenpox Vaccine

GlaxoSmithKline

Phase 3

1,209

Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina

2026-05-11

Recruiting

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

NCT07535034Gout

DrugDotinurad

Crystalys Therapeutics

Phase 2

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky

2026-05-08

Active, closed

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

NCT07480564Rett Syndrome

Taysha Gene Therapies, Inc.

Phase 3

Alabama, Illinois, Massachusetts

2026-05-08

Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT07326566Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)

DrugsTemodar·Temozolomide

Black Diamond Therapeutics, Inc.

Phase 2

162

Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Maryland

2026-05-05

Recruiting

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483Alpha 1 Antitrypsin Deficiency

Grifols Therapeutics LLC

Phase 3

Alabama, Arizona, California, Florida, Minnesota, Ohio, South Carolina, Texas

2026-05-05

Recruiting

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

DrugXNW27011

Astellas Pharma Global Development, Inc.

Phase 1/2

150

Alabama, California, Florida, Georgia, Indiana, Michigan, New Jersey, New York

2026-05-04

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Michigan

2026-05-04

Not yet open

Occlutech AFR Fontan Study

NCT07532369Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly

Occlutech International AB

Observational

Alabama, California, Colorado, Illinois, North Carolina, Texas

2026-05-01

Recruiting

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

NCT07610395Rhinovirus Infection

Altesa Biosciences, Inc.

Phase 2

180

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky

2026-05-01

Recruiting

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

NCT07335588Lichen Sclerosus

DrugDelgocitinib

LEO Pharma

Phase 3

652

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Minnesota

2026-05-01

Recruiting

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637Treatment-resistant Depression (TRD)

Alto Neuroscience

Phase 2

178

Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts

2026-05

Recruiting

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer

DrugsPelareorep·Avastin·Folfox·Bevacizumab

Oncolytics Biotech

Phase 2

Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan

2026-04-30

Recruiting

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

NCT07502508Type 2 Diabetes

DrugIcovamenib

Biomea Fusion Inc.

Phase 2

Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia

2026-04-30

Recruiting

Aquarius Pilot Study to Evaluate the New Axonics Trial System

NCT07335484Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)

Axonics, Inc.

Not applicable

Alabama, Georgia, South Carolina

2026-04-30

Not yet open

A Study of the Sleepnet Elara APAP Device

NCT07559708Sleep Apnea - Obstructive

Sleepnet Corporation

Not applicable

Alabama

2026-04-27

Recruiting

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

NCT07232030Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III

CVRx, Inc.

Not applicable

2,500

Alabama, Florida, Missouri, Nebraska, Ohio, South Dakota, Tennessee, Texas

2026-04-24

Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

NCT07502443Narcolepsy Type 2

DrugAlixorexton

Alkermes, Inc.

Phase 3

176

Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts

2026-04-22

Recruiting

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232Crohn Disease

DrugsRisankizumab·Guselkumab

Janssen Research & Development, LLC

Phase 3

530

Alabama, California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas

2026-04-21

Active, closed

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

NCT07503210Obesity

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

606

Alabama, California, Florida, Illinois, Indiana, North Carolina, Pennsylvania, Rhode Island

2026-04-21

Recruiting

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07489651Generalized Anxiety Disorder

DrugRE104

Reunion Neuroscience Inc

Phase 2

160

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan

2026-04-20

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland

2026-04-13

Recruiting

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

NCT07533175Diabetes Mellitus, Overweight, Obesity

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

630

Alabama, California, Florida, Minnesota, New York, South Carolina, Tennessee, Texas

2026-04-13

Recruiting

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

NCT06964087Type I Diabetes

DrugOPT101

Op-T LLC

Phase 2

Alabama, California, Colorado, Illinois, Washington

2026-04-10

Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073Solid Tumors

DrugINCB161734

Incyte Corporation

Phase 3

588

Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia

2026-04-09

Recruiting

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

NCT07519395Irritable Bowel Syndrome

DrugCamlipixant

GlaxoSmithKline

Phase 2

420

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-04-08

Recruiting

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

NCT07298473Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF)

Medtronic Cardiac Ablation Solutions

Not applicable

400

Alabama, California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio

2026-04-08

Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

NCT07424404Schizophrenia, Autism-Related Irritability

DrugsKarX-EC·KarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

400

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky

2026-04-07

Recruiting

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112Refractory Melanoma

DrugDOC1021

Diakonos Oncology Corporation

Phase 1/2

Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas

2026-04-06

Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

NCT07455383Narcolepsy Type 1

DrugAlixorexton

Alkermes, Inc.

Phase 3

150

Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts

2026-04-06

Not yet open

Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)

NCT07513506Growth

Mead Johnson Nutrition

Not applicable

214

Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas

2026-04-03

Recruiting

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

NCT07430956Atrial Fibrillation (AF)

DrugsAmrecibart·Cenvacibart

Regeneron Pharmaceuticals

Phase 3

2,628

Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana

2026-04-03

Recruiting

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

NCT07556159Asthma

Sanofi

Observational

2,500

Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland

2026-04-01

Recruiting

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465Cytomegalovirus Prophylaxis

DrugLetermovir

Merck Sharp & Dohme LLC

Phase 1

Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota

2026-03-30

Active, closed

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

NCT07502495Type 2 Diabetes

DrugIcovamenib

Biomea Fusion Inc.

Phase 2

Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia

2026-03-27

Recruiting

Continuous Dual Aspiration Technique With Zoom System for Stroke

NCT07491952Ischemic Stroke, Acute Stroke

Imperative Care, Inc.

Observational

750

Alabama, California, Florida, Georgia, Louisiana, Maryland, Minnesota, New York

2026-03-24

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 3

770

Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2026-03-24

Active, closed

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303Adult Obesity, Weight Management

DrugsECC4703·Semaglutide

Eccogene

Phase 2

151

Alabama, California, Florida, Georgia, Minnesota, Nebraska, North Carolina, Ohio

2026-03-23

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois

2026-03-23

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York

2026-03-23

Recruiting

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792Plaque Psoriasis

DrugORKA-002

Oruka Therapeutics, Inc.

Phase 2

160

Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan

2026-03-19

Recruiting

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603Lichen Planopilaris

DrugBrepocitinib

Priovant Therapeutics, Inc.

Phase 2/3

342

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana

2026-03-19

Recruiting

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung

DrugsMarlotamig·Ubamatamab·Sarilumab

Regeneron Pharmaceuticals

Phase 2

300

Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana

2026-03-18

Recruiting

Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device

NCT07456865Urge Urinary Incontinence

MedtronicNeuro

Not applicable

256

Alabama, Arizona, Idaho, Missouri, North Carolina, Ohio, Pennsylvania, South Carolina

2026-03-17

Recruiting

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT07473778HIV Infections

DrugsF/TAF·Emtricitabine/tenofovir disoproxil fumarate·Descovy·F/TDF

Gilead Sciences

Observational

3,000

Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland

2026-03-17

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky

2026-03-16

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky

2026-03-16

Recruiting

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

NCT07500090Idiopathic Hypersomnia

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

248

Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Michigan

2026-03-16

Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT07361510Non-Small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Pembrolizumab

Bristol-Myers Squibb

Phase 3

750

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2026-03-12

Recruiting

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

NCT07339111Knee Cartilage Defects

Medipost, Inc.

Phase 3

300

Alabama, Arizona, California, Colorado, Illinois, Kentucky, Louisiana, Michigan

2026-03-11

Recruiting

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177Non-segmental Vitiligo

DrugGIA632

Novartis Pharmaceuticals

Phase 2

210

Alabama, California, Florida, Illinois, Indiana, Maryland, Michigan, Nebraska

2026-03-09

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

DrugsIdelalisib·Pirtobrutinib

Eli Lilly and Company

Phase 4

150

Alabama, Arizona, Florida, Minnesota, New York, Ohio, Texas

2026-03-09

Recruiting

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

NCT07464314Influenza, Human+COVID-19

GlaxoSmithKline

Phase 1

225

Alabama, Arkansas, California, Florida, Georgia, Texas, Virginia, Washington

2026-03-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2026-03-05

Active, closed

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts

2026-03-03

Active, closed

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07427797Moderate to Severe Glabellar Lines

DrugCorabotase

Ipsen

Phase 3

309

Alabama, Arizona, California, Florida, Maryland, South Carolina, Texas, Virginia

2026-02-27

Recruiting

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

NCT07051707COPD, Chronic Obstructive Pulmonary Disease

Nuvaira, Inc.

Not applicable

200

Alabama, Florida, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, Wisconsin

2026-02-24

Recruiting

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853Healthy Adults

Pfizer

Phase 2

770

Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri

2026-02-23

Recruiting

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer

Radiopharm Theranostics, Ltd

Phase 1/2

Alabama, Michigan, Nebraska, Texas

2026-02-23

Recruiting

Study of DISC-0974-201 in Participants With IBD and Anemia

NCT07368972Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia

DrugDISC-0974

Disc Medicine, Inc

Phase 2

Alabama, Arizona, California, Florida, Missouri, Ohio, Rhode Island, Texas

2026-02-20

Recruiting

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT07284758Multiple Myeloma, Relapsed/Refractory Multiple Myeloma

DrugsCemsidomide·Dexamethasone

C4 Therapeutics, Inc.

Phase 2

100

Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan

2026-02-18

Recruiting

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852Glaucoma

DrugsGen 2 Travoprost Intracameral Implant·Timolol eye

Glaukos Corporation

Phase 3

510

Alabama

2026-02-17

Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497Locally Advanced / Metastatic Solid Tumors

Crescent Biopharma, Inc.

Phase 1/2

290

Alabama, California, Colorado, District of Columbia, Florida, Michigan, New York, Ohio

2026-02-17

Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

NCT07285018Diabetic Peripheral Neuropathic Pain

DrugLY4065967

Eli Lilly and Company

Phase 2

150

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-02-16

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maine

2026-02-16

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois

2026-02-16

Recruiting

Aspiration Thrombectomy Using the Symphony or Prodigy System

NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism

Imperative Care, Inc.

Observational

750

Alabama, Florida, Illinois, Indiana, Michigan, New York, North Carolina, Ohio

2026-02-13

Recruiting

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723Symptomatic Genetic Dilated Cardiomyopathy

DrugDanicamtiv

Kardigan, Inc.

Phase 2/3

332

Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts

2026-02-13

Recruiting

A Study of Patients With Fabry Disease (US Specific)

NCT06906367Fabry Disease

DrugMigalastat HCl

Amicus Therapeutics

Observational

450

Alabama, Arkansas, Georgia, Missouri, New York, Pennsylvania, Texas, Virginia

2026-02-13

Recruiting

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273Invasive Mould Infection

DrugVoriconazole

Elion Therapeutics, Inc.

Phase 2

Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas

2026-02-13

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease

Pfizer

Phase 2/3

1,156

Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana

2026-02-11

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-02-10

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

800

Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan

2026-02-10

Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931Osteoarthritis, Overweight or Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-02-09

Recruiting

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

NCT07388498Uncontrolled Gout

DrugMethotrexate

Amgen

Phase 3

270

Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-02-09

Active, closed

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441Multiple Myeloma

DrugRamantamig

Janssen Research & Development, LLC

Phase 2

168

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa

2026-02-08

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

NCT07321886Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

1,980

Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Iowa

2026-02-06

Recruiting

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

NCT07340320Type II Diabetes Mellitus

DrugCX11

Corxel Pharmaceuticals

Phase 2

240

Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts

2026-02-06

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

NCT07304089Dystonia

DrugVIM0423

Vima Therapeutics

Phase 2

100

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas

2026-02-05

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware

2026-02-03

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

NCT06696755Bipolar I Disorder, Bipolar II Disorder

DrugIcalcaprant

AbbVie

Phase 2

195

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri

2026-02-03

Recruiting

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

NCT06968845Idiopathic Pulmonary Fibrosis (IPF)

Rein Therapeutics

Phase 2

120

Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan

2026-02-02

Recruiting

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 2

Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky

2026-02-02

Recruiting

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

NCT06654193Acute Kidney Injury

Hope Biosciences LLC

Phase 1/2

Alabama, California, Texas

2026-02-01

Not yet open

Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

NCT07328542Hypogonadism, Male

DrugTestosterone Cypionate

Azurity Pharmaceuticals

Phase 4

144

Alabama, Florida, New York, Texas, Utah

2026-02

Recruiting

Renal Pelvic Denervation Pilot Trial

NCT07005050Uncontrolled Hypertension

Verve Medical, Inc

Not applicable

Alabama, Arizona, California, Illinois, Iowa, Minnesota, Nevada, Texas

2026-01-30

Recruiting

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT07428538Hepatitis

Bausch Health Americas, Inc.

Phase 3

350

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois

2026-01-29

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212Squamous Cell Carcinoma of Head and Neck

DrugsJNJ-90301900·Paclitaxel·Cisplatin·Carboplatin

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

Alabama, California, Florida, Georgia, Massachusetts, New York, North Carolina, Pennsylvania

2026-01-26

Recruiting

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

NCT07230288Idiopathic Pulmonary Fibrosis

AbbVie

Phase 2

165

Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia

2026-01-23

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703Cervical Cancer

DrugsMvasi·Sacituzumab tirumotecan·Paraplatin·Avastin

Merck Sharp & Dohme LLC

Phase 3

1,023

Alabama, Alaska, California, Florida, Georgia, Louisiana, Maryland, Minnesota

2026-01-19

Not yet open

Assessing Safety of Cervical Spine Fusion With NMP®

NCT07245940Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis Cervical

DrugNatural Matrix Protein (NMP) Fibers

Red Rock Regeneration Inc.

Observational

300

Alabama

2026-01-15

Recruiting

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

240

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky

2026-01-15

Recruiting

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292Multiple Sclerosis

DrugsMRI contrast-enhancing preparations·Frexalimab

Sanofi

Phase 3

160

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland

2026-01-14

Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480Multiple Myeloma, Secondary Immunodeficiency

Takeda

Phase 3

183

Alabama, California, Kansas, Maryland, Michigan, Missouri, New York

2026-01-14

Recruiting

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugsTulmimetostat·Prednisone/Prednisolone·Abiraterone·Darolutamide

Novartis Pharmaceuticals

Phase 1/2

181

Alabama, Iowa, Kansas, North Carolina, South Carolina, Utah

2026-01-13

Recruiting

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

NCT07382167Chronic Idiopathic Constipation (CIC)

DrugTenapanor

Ardelyx

Phase 3

692

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2026-01-13

Active, closed

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

NCT07284901Obesity With Diabetes, Overweight With Diabetes

DrugRibupatide

Kailera

Phase 3

1,270

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2026-01-12

Recruiting

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

NCT07301255Asthma

DrugENV-294

Enveda Therapeutics

Phase 2

Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky

2026-01-09

Recruiting

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

NCT07271186Diabetic Kidney Disease (DKD)

Regeneron Pharmaceuticals

Phase 2

195

Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-01-09

Recruiting

A Study of Buntanetap in Participants With PD

NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation

DrugBuntanetap/posiphen

Annovis Bio Inc.

Phase 2/3

500

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana

2026-01-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454Depressive Disorder, Major

DrugsEsketamine·Midazolam

Janssen Research & Development, LLC

Phase 3

258

Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio

2026-01-08

By invitation

Lead Evaluation for Defibrillation and Reliability Post Approval Study

NCT07005232Tachyarrhythmia

Medtronic

Observational

2,000

Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana

2026-01-07

Recruiting

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

NCT07222410COPD

Fisher and Paykel Healthcare

Not applicable

Alabama, Iowa, New York, Pennsylvania

2026-01-07

Recruiting

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

NCT07187973Sickle Cell Disease

DrugDISC-3405

Disc Medicine, Inc

Phase 1

Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio

2026-01-06

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky

2025-12-29

Recruiting

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

NCT07254806Degenerative Disc Disease

DiscGenics, Inc.

Phase 3

162

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Illinois

2025-12-23

Recruiting

Diagnosing Epilepsy To EffeCT Change

NCT07110337Epilepsy, Epilepsy (Treatment Refractory)

Epiminder America, Inc.

Not applicable

210

Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan

2025-12-23

Recruiting

Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

NCT07110454Epilepsy, Epilepsy (Treatment Refractory)

Epiminder America, Inc.

Observational

210

Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan

2025-12-23

Recruiting

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395Atopic Dermatitis (AD)

DrugENV-294

Enveda Therapeutics

Phase 2

105

Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky

2025-12-22

Recruiting

Impact of a Multiplex Respiratory PCR Test on Outcomes for Patients Presenting With Respiratory Illness in the Urgent Care Setting: A Hybrid-Effectiveness Quasi-Experimental Trial

NCT07513519Acute Respiratory Infections (ARIs)

BioMérieux

Not applicable

800

Alabama

2025-12-22

Active, closed

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875Obesity, Overweight

DrugRibupatide

Kailera

Phase 3

2,530

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2025-12-18

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

NCT07276997Major Depressive Disorder

DrugIcalcaprant

AbbVie

Phase 2

195

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada

2025-12-18

Recruiting

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

NCT07091019Chronic Myelogenous Leukemia - Chronic Phase

Novartis Pharmaceuticals

Observational

1,000

Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York

2025-12-17

Recruiting

Study of DONQ52 in Active Celiac Disease

NCT07239336Celiac Disease

Chugai Pharmaceutical

Phase 2

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana

2025-12-16

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

1,035

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2025-12-15

Recruiting

A Long-term Follow-up Study in Patients Who Received BEAM-101

NCT07373639Hemoglobinopathy, Sickle Cell Disease

Beam Therapeutics Inc.

Observational

Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri

2025-12-15

Recruiting

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

NCT07226349Advanced Solid Tumor

DrugsBGB-43395·Fulvestrant

BeOne Medicines

Phase 1

105

Alabama, California, Connecticut, Maryland, Massachusetts, Texas, Wisconsin

2025-12-11

Recruiting

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267Breast Cancer, Advanced Solid Tumor

DrugBG-75202

BeOne Medicines

Phase 1

Alabama, Connecticut, Missouri, Texas, Washington

2025-12-11

Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders

DrugCYB003

Cybin IRL Limited

Phase 3

330

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2025-12-10

Recruiting

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

NCT07282665Clostridoides Difficile Associated Disease

Pfizer

Phase 3

32,500

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois

2025-12-10

Active, closed

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839COVID-19, SARS-COV-2 Infection

DrugBNT162b2 Vaccine

BioNTech SE

Phase 3

5,240

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2025-12-10

Active, closed

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945Chronic Kidney Disease

DrugDapagliflozin

Boehringer Ingelheim

Phase 3

135

Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland

2025-12-09

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2025-12-04

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

366

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana

2025-12-03

Recruiting

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus

DrugSurovatamig

AstraZeneca

Phase 1

Alabama, California, Florida, Missouri, Texas

2025-12-02

Recruiting

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

NCT07258849Rheumatoid Arthritis (RA)

Eli Lilly and Company

Phase 1

141

Alabama, Arizona, Florida, Nevada

2025-12-02

Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281Atopic Dermatitis

DrugAbrocitinib

Pfizer

Phase 3

450

Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina

2025-12-02

Active, closed

A Study of DII235 in Adults With Elevated Lipoprotein(a)

NCT07235046Lipoprotein Disorder

Novartis Pharmaceuticals

Phase 2

234

Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland

2025-12-02

Active, closed

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

NCT07400588Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss

DrugAleniglipron

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 2

Alabama, California, Missouri, Ohio, South Carolina, Tennessee, Texas

2025-12-01

Active, closed

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654Pneumococcal Vaccines

Drugs31-valent pneumococcal conjugate vaccine·Capvaxive·Prevnar 20

Vaxcyte, Inc.

Phase 3

4,049

Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana

2025-12-01

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

DrugRina-S

Genmab

Phase 3

660

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois

2025-11-28

Recruiting

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

NCT07236099Prurigo Nodularis (PN)

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

135

Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska

2025-11-27

Active, closed

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558SARS-CoV-2

DrugsMNEXSPIKE·Spikevax

ModernaTX, Inc.

Phase 4

30,000

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2025-11-26

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2025-11-25

Active, closed

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

NCT07232004Healthy Volunteer, Psoriasis

AbbVie

Phase 1

142

Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri

2025-11-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2025-11-24

Active, closed

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

NCT07217015Atopic Dermatitis

DrugKT-621

Kymera Therapeutics, Inc.

Phase 2

200

Alabama, Arkansas, California, Florida, Illinois, Michigan, New York, North Dakota

2025-11-24

Recruiting

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419Diabetic Peripheral Neuropathic Pain

DrugSuzetrigine

Vertex Pharmaceuticals Incorporated

Phase 3

734

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2025-11-21

Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant

DrugsMIRV·Mirvetuximab Soravtansine·Bevacizumab·Carboplatin

AbbVie

Phase 2

140

Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana

2025-11-21

Active, closed

Efficacy and Safety of NVX-CoV2705

NCT07086222COVID-19, Sars-CoV-2 Infection

Novavax

Phase 4

6,500

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho

2025-11-20

Active, closed

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)

DrugVX-407

Vertex Pharmaceuticals Incorporated

Phase 2

Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas

2025-11-19

Active, closed

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685Alport Syndrome

Bayer

Phase 2

Alabama, Florida, Georgia, Idaho, Massachusetts, Texas

2025-11-19

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia

2025-11-18

Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803Atopic Dermatitis

Sanofi

Observational

1,000

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan

2025-11-17

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Alabama, California, Florida, Michigan, Ohio, Oklahoma

2025-11-14

Recruiting

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant

ACADIA Pharmaceuticals Inc.

Phase 2

153

Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska

2025-11-14

Active, closed

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim

Phase 2

Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina

2025-11-13

Recruiting

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07023627Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 2

160

Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky

2025-11-12

Recruiting

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

NCT07281079Phelan-McDermid Syndrome

DrugNNZ-2591

Neuren Pharmaceuticals Limited

Phase 3

160

Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan

2025-11-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii

2025-11-11

Active, closed

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482Hyperlipidemia

DrugsEnlicitide·Enlicitide Decanoate·Rosuvastatin

Merck Sharp & Dohme LLC

Phase 3

996

Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas

2025-11-11

Recruiting

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

NCT07228364Autosomal Dominant Polycystic Kidney Disease

DrugAZD1613

AstraZeneca

Phase 1

Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas

2025-11-10

Recruiting

Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)

NCT07216872Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Alcohol Dependence

Brainsway

Not applicable

186

Alabama, California, Florida, Illinois, New York, Ohio, Oregon, West Virginia

2025-11-07

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan

2025-11-07

Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225Non-muscle Invasive Bladder Cancer

DrugSasanlimab

Pfizer

Phase 1

294

Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York

2025-11-06

Active, closed

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

NCT07220759Overweight, Obesity, Type 2 Diabetes

DrugCagrilintide

Novo Nordisk A/S

Phase 3

330

Alabama, Arizona, California, Florida, Hawaii, Indiana, Nevada, New York

2025-11-05

Recruiting

Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection

Artivion Inc.

Not applicable

132

Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland

2025-11-04

Not yet open

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NCT07217639COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus

Aptitude Medical Systems

Not applicable

2,000

Alabama

2025-11-01

Recruiting

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT07142356Uncontrolled Hypertension

Retension Pharmaceuticals. Inc.

Phase 2

280

Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Louisiana

2025-10-31

Recruiting

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593Peripheral Arterial Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,205

Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan

2025-10-31

Recruiting

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051Bronchiectasis

DrugGSK3862995B

GlaxoSmithKline

Phase 2

363

Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland

2025-10-30

Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

NCT06701656Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome

DrugBevacizumab

PPD Development, LP

Phase 2

200

Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts

2025-10-28

Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer

Tempus AI

Observational

900

Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada

2025-10-27

Recruiting

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy

Alexion Pharmaceuticals, Inc.

Phase 1/2

Alabama, California, Massachusetts, Ohio, Oregon, Pennsylvania, Texas

2025-10-24

Recruiting

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

NCT07069738Heart Failure - NYHA II - IV

Boston Scientific Corporation

Not applicable

850

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho

2025-10-22

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2025-10-22

Recruiting

Pivotal Study of the Velocity™ pAVF System

NCT07153939Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)

Venova Medical

Not applicable

126

Alabama, California, Florida, New York, North Carolina, South Carolina, Texas

2025-10-21

Recruiting

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

NCT07175428Atrial Fibrillation (AF)

DrugsAmrecibart·Cenvacibart·Apixaban

Regeneron Pharmaceuticals

Phase 2

1,200

Alabama, California, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts

2025-10-20

Active, closed

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

NCT07074977Chronic Pruritus of Unknown Origin

DrugNemolizumab

Galderma R&D

Phase 2

Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan

2025-10-20

Recruiting

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

NCT07143669Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease

Blueprint Medicines Corporation

Observational

750

Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana

2025-10-17

Recruiting

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

NCT07219966Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Maryland

2025-10-15

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2025-10-15

Recruiting

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

NCT07219771Knee Osteoarthritis

Doron Therapeutics Inc.

Phase 3

260

Alabama, California, Florida, Illinois, Pennsylvania, South Carolina, Utah

2025-10-14

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Alabama, Connecticut, Florida, Georgia, Indiana, Maine, New Jersey, New York

2025-10-08

Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488Multiple Myeloma

DrugsMezigdomide·Elranatamab·Dexamethasone

Celgene

Phase 1/2

Alabama, Connecticut, New Jersey, Texas

2025-10-07

Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsVisugromab·Visugromab RDE·Opdivo·Docetaxel

CatalYm GmbH

Phase 2

131

Alabama, California, New York, North Carolina

2025-10-07

Active, closed

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant

DrugSparsentan

Travere Therapeutics, Inc.

Phase 4

Alabama, New York, North Carolina, Ohio, Texas, Washington, Wisconsin

2025-10-07

Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106Breast Cancer

DrugsRGT-419B·Giredestrant·Abemaciclib

Genentech, Inc.

Phase 1/2

285

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maine

2025-10-07

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Hawaii

2025-10-03

Recruiting

Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty

NCT07191067Pain

Synaptrix, Inc.

Not applicable

120

Alabama, New York, North Carolina, Oregon, Washington

2025-09-30

Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275Primary Membranous Nephropathy

DrugsPovetacicept·Tacrolimus

Vertex Pharmaceuticals Incorporated

Phase 2/3

176

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2025-09-30

Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07116616Relapsed or Refractory Multiple Myeloma

ModernaTX, Inc.

Phase 1/2

190

Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee

2025-09-30

Recruiting

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

NCT07202884Urinary Incontinence,Stress

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,000

Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania

2025-09-30

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia

2025-09-29

Recruiting

TLN-372 in Advanced KRAS Mutant Solid Tumors

NCT07204340KRAS Mutant Solid Tumors

DrugsCetuximab·Pembrolizumab

Treeline Biosciences, Inc.

Phase 1

270

Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois

2025-09-28

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

NCT07159763Influenza

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

10,000

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2025-09-25

Active, closed

SPHERE Per-AF Post-Approval Study

NCT06858306Persistent Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

200

Alabama, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania

2025-09-25

Recruiting

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia

DrugSetmelanotide

Rhythm Pharmaceuticals, Inc.

Phase 3

Alabama, Colorado, Illinois, Massachusetts, Minnesota, New York, Pennsylvania, Washington

2025-09-23

Recruiting

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT07053423Chronic Obstructive Pulmonary Disease

DrugDupilumab

Sanofi

Phase 4

218

Alabama, Florida, Georgia, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2025-09-22

Recruiting

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

NCT06827990Aortic Dissection

W.L.Gore & Associates

Not applicable

112

Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan

2025-09-22

Recruiting

DESTINY-PANTUMOUR04

NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Observational

100

Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico

2025-09-18

Active, closed

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,101

Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Louisiana

2025-09-17

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois

2025-09-17

Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

DrugEmpasiprubart

argenx

Phase 3

160

Alabama, California, Colorado, District of Columbia, Florida, Louisiana, Pennsylvania, Tennessee

2025-09-16

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

414

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2025-09-13

Recruiting

Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

NCT06784466Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF

Arga Medtech SA

Not applicable

360

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas

2025-09-10

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2025-09-06

Recruiting

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

NCT06726161Hepatocellular Carcinoma (HCC)

RayzeBio, Inc.

Phase 1/2

590

Alabama, Arizona, California, Florida, Kentucky, Maryland, Minnesota, Missouri

2025-09-05

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Iowa

2025-09-04

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

140

Alabama, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota

2025-09-02

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho

2025-09-02

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321Invasive Mold Infections

DrugFosmanogepix

Basilea Pharmaceutica

Phase 3

234

Alabama, California, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota

2025-08-26

Recruiting

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244Healthy

DrugPrevnar 20

Pfizer

Phase 3

6,000

Alabama, Arizona, California, Colorado, Florida, Idaho, Louisiana, Maryland

2025-08-25

Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

DrugsEmpasiprubart·IVIG

argenx

Phase 3

218

Alabama, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland

2025-08-22

Recruiting

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

11,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2025-08-22

Recruiting

Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)

NCT07135284Bronchiectasis Adult

Synchrony-Medical, Ltd

Observational

200

Alabama, Georgia, South Carolina

2025-08-20

Recruiting

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone

Astellas Pharma Global Development, Inc.

Phase 2

218

Alabama, California, Florida, Illinois, Louisiana, New Mexico, Ohio, South Carolina

2025-08-19

Recruiting

Abbott Cephea Mitral Valve Disease Registry

NCT07069673Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation

Abbott Medical Devices

Observational

1,000

Alabama, Arizona, California, Georgia, Illinois, Indiana, Kansas, Minnesota

2025-08-13

Recruiting

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06975865Sickle Cell Disease

DrugRilzabrutinib

Sanofi

Phase 3

192

Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Louisiana

2025-08-12

Recruiting

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

DrugORX750

Centessa Pharmaceuticals (UK) Limited

Phase 2

Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio

2025-08-12

Active, closed

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

NCT07076199Diabetes Mellitus, Type 1

DrugsInsulin aspart·Insulin glargine·Insulin icodec

Novo Nordisk A/S

Phase 3

877

Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana

2025-08-11

Recruiting

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

NCT06988618Prurigo Nodularis

Galderma R&D

Observational

600

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana

2025-08-11

Recruiting

Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT

NCT05337241Refractory Ventricular Tachycardia

Thermedical, Inc.

Not applicable

130

Alabama, Pennsylvania, South Carolina, Tennessee, Utah

2025-08-09

Recruiting

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

NCT02880163Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic

Arsenal Medical, Inc.

Not applicable

Alabama, Ohio

2025-08-07

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Iowa, Nebraska

2025-08-06

Recruiting

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

NCT07133308Alopecia Areata

DrugDeuruxolitinib

Sun Pharmaceutical Industries, Inc.

Phase 3

355

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2025-08-05

Recruiting

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

NCT07089888Tophaceous Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

250

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2025-08-04

Recruiting

Evaluation of Accuracy of the Owlet OSS 3.0 Sensor in the Neonatal Population

NCT06771206Pulse Oximeter Validation

Owlet Baby Care, Inc.

Not applicable

Alabama, Minnesota

2025-08-01

Recruiting

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer

DrugsPalbociclib·Fulvestrant

Bristol-Myers Squibb

Phase 1

234

Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas

2025-08-01

Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

500

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2025-08-01

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Visugromab RDE

CatalYm GmbH

Phase 2

107

Alabama, California, Connecticut, Florida, New York, North Carolina, South Carolina

2025-08-01

Active, closed

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis

DrugMK-8527

Merck Sharp & Dohme LLC

Phase 3

4,390

Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Mississippi

2025-07-31

Recruiting

WRAP North America

NCT06807099Venous Stenosis, Venous Occlusion

Merit Medical Systems, Inc.

Observational

250

Alabama, Arizona, California, Florida, Kentucky, Rhode Island, South Carolina, Tennessee

2025-07-31

Recruiting

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034Adjustment Disorder

DrugRE104

Reunion Neuroscience Inc

Phase 2

100

Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois

2025-07-30

Recruiting

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805Chronic Rhinosinusitis Without Nasal Polyps

Optinose US Inc.

Phase 3

Alabama, Arizona, California, Colorado, Georgia, Illinois, Kentucky, Maryland

2025-07-28

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Alabama, Alaska, Arkansas, California, Florida, Georgia, Illinois, Iowa

2025-07-28

Active, closed

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

NCT07146022Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia

DrugVDPHL01

Veradermics, Inc.

Phase 3

552

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2025-07-25

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois

2025-07-25

Recruiting

Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

NCT07070115Hiatal Hernia

Tela Bio Inc

Not applicable

173

Alabama, Colorado, Kentucky, North Carolina, Texas

2025-07-25

Recruiting

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268Eczema

DrugAbrocitinib

Pfizer

Phase 3

150

Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina

2025-07-24

Recruiting

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NCT06911632Pulmonary Hypertension, Interstitial Lung Disease (ILD)

Tempus AI

Not applicable

900

Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana

2025-07-23

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2025-07-22

Active, closed

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

NCT07047716HIV Pre-exposure Prophylaxis

DrugLenacapavir

Gilead Sciences

Phase 3

339

Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Louisiana

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Alabama, Arizona, California, Colorado, Delaware, Florida, Kentucky, New Jersey

2025-07-21

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Alabama, Arizona, California, District of Columbia, Florida, Kentucky, Louisiana, Massachusetts

2025-07-21

Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

NCT06824168Acute Myeloid Leukemia, Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 2

130

Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania

2025-07-18

Recruiting

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

NCT06891755COPD, Emphysema

Apreo Health, Inc.

Not applicable

250

Alabama, Arizona, California, Florida, Illinois, Kansas, Massachusetts, Michigan

2025-07-15

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana

2025-07-15

Recruiting

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

NCT06988605Atopic Dermatitis

Galderma R&D

Observational

1,000

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana

2025-07-14

Active, closed

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212Chronic Spontaneous Urticaria (CSU)

DrugsRemibrutinib·Dupilumab

Novartis Pharmaceuticals

Phase 3

409

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2025-07-11

Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA

Artiva Biotherapeutics, Inc.

Phase 2

Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Montana

2025-07-09

Recruiting

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

NCT06714864Catheter-Related Infections

Drug(taurolidine and heparin) catheter lock

CorMedix Therapeutics

Phase 4

Alabama, Arizona, California, Delaware, New Jersey, Texas

2025-07-08

Recruiting

Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

NCT07048808Refractory Angina, Coronary Artery Disease

XyloCor Therapeutics, Inc.

Phase 2

106

Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina

2025-07-08

Active, closed

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

NCT07076407Major Depressive Disorder

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

450

Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2025-07-08

Recruiting

Radiation Free Study

NCT06549348Aortic Aneurysm

Philips Clinical & Medical Affairs Global

Not applicable

182

Alabama, Massachusetts, Pennsylvania, Texas

2025-07-03

Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352Alzheimers Disease

Hoffmann-La Roche

Phase 3

80,000

Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Illinois

2025-07-02

Recruiting

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)

BiomX Ltd

Phase 2

Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York

2025-07-02

Recruiting

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277Prostate Cancer

DrugsAAA817·ARPI

Novartis Pharmaceuticals

Phase 3

940

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa

2025-07-01

Active, closed

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

NCT06966453Breast Cancer, Breast Neoplasms

DrugDisitamab Vedotin

Pfizer

Phase 1/2

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Oregon

2025-06-30

Recruiting

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

NCT07028749Hypertriglyceridemia

DrugMAR001

Marea Therapeutics

Phase 2

316

Alabama, Arkansas, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky

2025-06-27

Recruiting

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Alabama, Arizona, California, Colorado, Florida, Kentucky, Michigan, Minnesota

2025-06-27

Recruiting

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

NCT07001800Moderate Aortic Valve Stenosis

Kardigan, Inc.

Phase 2/3

1,276

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky

2025-06-27

Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

Alabama, Arkansas, California, Illinois, Indiana, Kansas, Maryland, Massachusetts

2025-06-27

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky

2025-06-27

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana

2025-06-26

Recruiting

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

NCT07113522Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease

DrugMT-201

Mirador Therapeutics, Inc.

Phase 2

140

Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Illinois, Louisiana

2025-06-26

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho

2025-06-25

Recruiting

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

NCT07015905Venous Thromboembolism (VTE)

DrugsCenvacibart·Enoxaparin·Apixaban

Regeneron Pharmaceuticals

Phase 3

2,000

Alabama, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, North Carolina

2025-06-25

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2025-06-24

Active, closed

VK2735 for Weight Management Phase 3

NCT07104500Weight Loss

DrugVK2735

Viking Therapeutics, Inc.

Phase 3

4,500

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2025-06-23

Active, closed

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

NCT07104383Weight Loss

DrugVK2735

Viking Therapeutics, Inc.

Phase 3

1,100

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii

2025-06-23

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

961

Alabama, Colorado, Florida, Georgia, Idaho, Illinois, Louisiana, Maine

2025-06-23

Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

NCT06701682Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome

DrugVilobelimab

PPD Development, LP

Phase 2

200

Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts

2025-06-21

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Alabama, Arizona, Colorado, Florida, Georgia, Idaho, Illinois, Maryland

2025-06-17

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana

2025-06-17

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

573

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2025-06-12

Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome

DrugParidiprubart

PPD Development, LP

Phase 2

200

Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts

2025-06-10

Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

NCT06703073Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome

DrugsParidiprubart·Vilobelimab·Bevacizumab

PPD Development, LP

Phase 2

600

Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts

2025-06-10

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2025-06-09

Active, closed

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235Hidradenitis Suppurativa

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

149

Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Massachusetts

2025-06-09

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

NCT06808984Agitation, Alzheimer Disease

DrugIrafamdastat

Celgene

Phase 2

120

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii

2025-06-09

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Iowa

2025-06-09

Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490Multiple Sclerosis Spasticity

DrugIrafamdastat

Celgene

Phase 2

200

Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri

2025-06-05

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Alabama, Arizona, Arkansas, California, Colorado, Delaware, Florida, Illinois

2025-06-04

Active, closed

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534Persistent Atrial Fibrillation

Boston Scientific Corporation

Not applicable

376

Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois

2025-06-03

Recruiting

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

NCT06961565NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)

DrugPAS-004

Pasithea Therapeutics Corp.

Phase 1

Alabama

2025-05-30

Active, closed

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Blueprint Medicines Corporation

Phase 2

105

Alabama, Arkansas, California, Florida, Idaho, Illinois, Indiana, Kentucky

2025-05-28

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana

2025-05-28

Recruiting

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

NCT06976268Parkinson Disease

Biohaven Therapeutics Ltd.

Phase 2/3

550

Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts

2025-05-28

Recruiting

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsREGN10597·Ubamatamab·Sarilumab·Fianlimab

Regeneron Pharmaceuticals

Phase 2

297

Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan

2025-05-28

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2025-05-27

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Alabama, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Iowa

2025-05-22

Recruiting

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800Primary Membranous Nephropathy

DrugsFelzartamab·Tacrolimus

Biogen

Phase 3

180

Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Georgia, Illinois

2025-05-22

Active, closed

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590Idiopathic Hypersomnia

DrugALKS 2680

Alkermes, Inc.

Phase 2

126

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois

2025-05-22

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan

2025-05-20

Active, closed

Pelacarsen Roll-over Extension Program

NCT06875973Atherosclerotic Cardiovascular Disease

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

599

Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland

2025-05-19

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts

2025-05-16

Active, closed

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519Rheumatoid Arthritis

Gilead Sciences

Phase 1

Alabama, California, Florida, Illinois, Louisiana, Oklahoma, Pennsylvania, Texas

2025-05-14

Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

425

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas

2025-05-12

Recruiting

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

NCT06952699Narcolepsy Type 2

DrugTAK-360

Takeda

Phase 2

Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan

2025-05-06

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

DrugsCetuximab·Docetaxel

Revolution Medicines, Inc.

Phase 3

590

Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas

2025-05-06

Active, closed

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805Idiopathic Pulmonary Fibrosis

Mediar Therapeutics

Phase 2

168

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas

2025-05-05

Active, closed

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity

DrugsRO7204239·Tirzepatide

Hoffmann-La Roche

Phase 2

285

Alabama, California, Florida, Georgia, Illinois, New York, North Carolina, Ohio

2025-05-05

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD5492

AstraZeneca

Phase 1

Alabama, California, Iowa, Nebraska, North Carolina

2025-05-01

Active, closed

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)

DrugsPelacarsen·Inclisiran

Novartis Pharmaceuticals

Phase 3

246

Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland

2025-04-30

Recruiting

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

NCT06394869Hematuria - Cause Not Known

Pacific Edge Limited

Not applicable

1,000

Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York

2025-04-29

Recruiting

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

NCT06846320Generalized Anxiety Disorder (GAD)

DrugABBV-932

AbbVie

Phase 2

315

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas

2025-04-29

Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

DrugAtezolizumab

SystImmune Inc.

Phase 1

120

Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York

2025-04-28

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois

2025-04-24

Recruiting

Access Cannulation Trial II

NCT05490225Dialysis; Complications, Vascular Access Complication

Voyager Biomedical

Not applicable

100

Alabama, California, Massachusetts, New York, South Carolina, Texas, Virginia

2025-04-23

Recruiting

Pivotal Study for the Cardiac Performance System (CPS)

NCT06870591Cardiovascular Diseases

Sensydia Corporation

Observational

1,000

Alabama, Illinois, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Tennessee

2025-04-22

Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

NCT06953869Insomnia Disorder

DrugTasimelteon

Vanda Pharmaceuticals

Phase 3

420

Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Montana

2025-04-21

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Maryland

2025-04-17

Recruiting

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

NCT06866405RSV Infection

DrugRSVpreF

Pfizer

Phase 3

550

Alabama, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas

2025-04-16

Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401Major Depressive Disorder

DrugNBI-1065845

Neurocrine Biosciences

Phase 3

850

Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts

2025-04-16

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa

2025-04-15

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884Lymphoma, Large B-Cell, Diffuse

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Polatuzumab Vedotin

Merck Sharp & Dohme LLC

Phase 2

594

Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida

2025-04-11

Active, closed

ASCEND CSP IDE Study

NCT06830746Heart Failure, Ventricular Arrythmia

Abbott Medical Devices

Not applicable

414

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Massachusetts, New York

2025-04-11

Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer

DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab

Corcept Therapeutics

Phase 2

270

Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon

2025-04-11

By invitation

Health App Data Collection Study

NCT06595615Cardiac Disease

Abbott Medical Devices

Observational

Alabama

2025-04-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Kansas

2025-04-09

Active, closed

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

NCT06868264HEPATITIS C VIRUS CHRONIC INFECTION

DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir

Atea Pharmaceuticals, Inc.

Phase 3

880

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2025-04-07

By invitation

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

300

Alabama, Arizona, Kansas, Pennsylvania

2025-04-01

Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945Alopecia Areata

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 3

674

Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa

2025-04-01

Recruiting

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06911112Major Depressive Disorder

DrugNBI-1065845

Neurocrine Biosciences

Phase 3

200

Alabama, Arkansas, California, Florida, Georgia, Massachusetts, Missouri, New York

2025-03-31

Recruiting

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

NCT06581328Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 4

200

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois

2025-03-27

Recruiting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT06655246Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant

DrugsZiftomenib·Imatinib

Kura Oncology, Inc.

Phase 1

157

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa

2025-03-27

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia

2025-03-27

Active, closed

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

NCT06857955Hypertension

DrugQCZ484

Novartis Pharmaceuticals

Phase 2

396

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana

2025-03-26

Recruiting

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

NCT06635785Advanced Solid Tumor

OncoC4, Inc.

Phase 1/2

387

Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan

2025-03-26

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

NCT06878261Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois

2025-03-25

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

Alabama, Florida, New Jersey, Texas, Virginia

2025-03-25

By invitation

LinkSymphoKnee (LSK) Total Knee Replacement System Study - Ultra-congruent (UC)

NCT06670651Osteoarthritis (OA) of the Knee, Fracture, Rheumatoid Arthritis

LinkBio Corp.

Observational

600

Alabama, Illinois

2025-03-21

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128MTAP-deleted Solid Tumors

Bayer

Phase 1/2

450

Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee

2025-03-21

Active, closed

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

157

Alabama, Arizona, Arkansas, California, Colorado, Florida, Maryland, Massachusetts

2025-03-20

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts

2025-03-20

Active, closed

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912Lung Neoplasm Malignant

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Ribociclib·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 2

Alabama, California, Colorado, Maryland, Oregon, Texas, Virginia

2025-03-20

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana

2025-03-18

Active, closed

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

1,105

Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa

2025-03-17

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2025-03-17

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho

2025-03-16

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia

2025-03-14

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois

2025-03-13

Active, closed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

NCT06869785Relapsing Multiple Sclerosis (RMS)

Novartis Pharmaceuticals

Phase 3

196

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana

2025-03-13

Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

NCT06788756Acute Myeloid Leukaemia (AML)

DrugCytarabine

Moleculin Biotech, Inc.

Phase 2/3

312

Alabama, Florida, Georgia, Nebraska, New Jersey, Ohio, Pennsylvania, Rhode Island

2025-03-12

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Alabama, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Minnesota

2025-03-12

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho

2025-03-12

Active, closed

Safety and Efficacy of VDPHL01 in Males With AGA

NCT06972264Androgenetic Alopecia, AGA, Male Pattern Baldness

DrugVDPHL01

Veradermics, Inc.

Phase 3

480

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas

2025-03-11

Active, closed

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR

DrugALXN2030

Alexion Pharmaceuticals, Inc.

Phase 2

Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey

2025-03-07

Active, closed

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987APOL1-Mediated Kidney Disease

AstraZeneca

Phase 2

Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland

2025-03-05

Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 3

300

Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa

2025-03-05

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2025-03-03

Recruiting

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055Non-small Cell Lung Cancer

DrugsPumitamig·Docetaxel

BioNTech SE

Phase 2

Alabama, Florida, Kentucky, New York, Texas

2025-03-03

Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316Hepatocellular Carcinoma

Bayer

Phase 1

148

Alabama, California

2025-02-28

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana

2025-02-28

Active, closed

A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.

NCT06922955Nasal Airway Obstruction

Aerin Medical

Observational

400

Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan

2025-02-28

Recruiting

A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

NCT06884865Osteoarthritis (OA) of the Knee

Pacira Pharmaceuticals, Inc

Phase 2

135

Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland

2025-02-26

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina

2025-02-25

Recruiting

Prevail Global Study

NCT06535854Coronary Artery Disease

Medtronic Vascular

Not applicable

1,205

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2025-02-24

Recruiting

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

NCT06797518Glomerulonephritis, IGA, Immunoglobulin A Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 2

Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas

2025-02-21

Active, closed

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain

Dogwood Therapeutics Inc.

Phase 2

240

Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Missouri

2025-02-21

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts

2025-02-19

Active, closed

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194Pneumococcal Immunization

DrugsHavrix·Vaqta·M-M-R II vaccine·Prevnar 20 vaccine

Sanofi

Phase 3

2,360

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho

2025-02-18

Recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268Sickle Cell Disease

DrugEtavopivat

Novo Nordisk A/S

Phase 3

510

Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida

2025-02-17

Active, closed

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

NCT06811909Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis

BioStem Technologies

Not applicable

Alabama, California, Florida, Illinois, Massachusetts, Missouri, New York, Texas

2025-02-14

Recruiting

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505Chronic Migraine

DrugAtogepant

AbbVie

Phase 3

420

Alabama, Arkansas, California, Florida, Indiana, Michigan, Mississippi, Nebraska

2025-02-13

Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819Advanced Solid Tumors, HER2 Mutation

DrugSevabertinib

Bayer

Phase 2

111

Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas

2025-02-13

Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 3

256

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Hawaii, Illinois

2025-02-10

Recruiting

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

NCT06541847Neurofibromatosis Type 1

Healx Limited

Phase 2

Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri

2025-02-10

Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098Thrombocytopenia, Neonatal Alloimmune

DrugsImmunoglobulins·Nipocalimab·IVIG·Prednisone

Janssen Research & Development, LLC

Phase 3

Alabama, California, Colorado, Illinois, Indiana, Iowa, New York, North Carolina

2025-02-10

Recruiting

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Cytokinetics

Phase 2

Alabama, Arizona, Arkansas, California, Florida, Illinois, Louisiana, Massachusetts

2025-02-06

Recruiting

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

NCT06777368Aortic Stenosis

Medtronic Cardiovascular

Observational

225

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana

2025-02-06

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Alabama, California, Florida, Illinois, Kentucky, Louisiana, Maryland, Ohio

2025-02-06

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana

2025-02-05

Recruiting

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

NCT06830629Proteinuric Kidney Disease

Maze Therapeutics

Phase 2

Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky

2025-02-05

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania

2025-02-04

Recruiting

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT06547489Major Depressive Disorder

DrugZelquistinel

Syndeio Biosciences, Inc

Phase 2

164

Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas

2025-02-03

By invitation

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

170

Alabama, Arizona, Arkansas, California, Colorado, Illinois, Missouri, Nevada

2025-02-01

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Alabama, Arizona, California, Colorado, Delaware, Florida, Illinois, Iowa

2025-01-28

Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

DrugALKS 2680

Alkermes, Inc.

Phase 2/3

786

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois

2025-01-27

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2025-01-27

Recruiting

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

NCT06548360NonSegmental Vitiligo

DrugRuxolitinib

Incyte Corporation

Phase 3

180

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2025-01-24

Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease

United Therapeutics

Observational

900

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois

2025-01-23

Recruiting

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

NCT06641414Higher-risk Myelodysplastic Syndrome

DrugsLisaftoclax·Azacitidine

Ascentage Pharma Group Inc.

Phase 3

490

Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Iowa

2025-01-22

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois

2025-01-21

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/alabama

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,302 of those studies with a site in Alabama.

How many clinical trials are recruiting in Alabama?

672 of the 1,302 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 13 have not yet opened recruitment, 583 are active but closed to new participants, and 34 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Alabama), 1,302 studies
Phase	Studies	Recruiting	Share
Phase 3	584	285	44.9%
Phase 2	249	137	19.1%
Not applicable	131	57	10.1%
Observational	125	65	9.6%
Phase 1/2	77	47	5.9%
Phase 1	70	44	5.4%
Phase 2/3	39	25	3%
Phase 4	27	12	2.1%

Most active sponsors

Lead sponsors with the most studies (Alabama)
Lead sponsor	Studies	Recruiting
AstraZeneca	67	40
Novartis Pharmaceuticals	50	21
Eli Lilly and Company	49	30
AbbVie	44	19
Hoffmann-La Roche	38	12
Merck Sharp & Dohme LLC	38	17
Pfizer	34	25
Janssen Research & Development, LLC	31	10
Sanofi	28	10
Bristol-Myers Squibb	25	12

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.